NRXBF (NurExone Biologic) Cash-to-Debt : 81.39 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NurExone Biologic's cash to debt ratio for the quarter that ended in Sep. 2024 was 81.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NurExone Biologic could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for NurExone Biologic's Cash-to-Debt or its related term are showing as below:

NRXBF' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.44 Med: 96.78 Max: 386.75
Current: 81.38

During the past 3 years, NurExone Biologic's highest Cash to Debt Ratio was 386.75. The lowest was 1.44. And the median was 96.78.

NRXBF's Cash-to-Debt is ranked better than
76.06% of 1483 companies
in the Biotechnology industry
Industry Median: 7.56 vs NRXBF: 81.38

NurExone Biologic Cash-to-Debt Historical Data

The historical data trend for NurExone Biologic's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NurExone Biologic Cash-to-Debt Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

2.12

55.98

27.05

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial									381.00	27.05	135.63	95.40	81.39

Competitive Comparison of NurExone Biologic's Cash-to-Debt

For the Biotechnology subindustry, NurExone Biologic's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

NurExone Biologic Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NurExone Biologic's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.541	/	(0.018	+	0.002)
	=	27.05

NurExone Biologic's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.523	/	(0	+	0.031)
	=	81.39

NurExone Biologic (OTCPK:NRXBF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NurExone Biologic Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

J90:Germany NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.